JP2000502714A - ヒアルロン酸の型の有効量の経口投与 - Google Patents

ヒアルロン酸の型の有効量の経口投与

Info

Publication number
JP2000502714A
JP2000502714A JP9524694A JP52469497A JP2000502714A JP 2000502714 A JP2000502714 A JP 2000502714A JP 9524694 A JP9524694 A JP 9524694A JP 52469497 A JP52469497 A JP 52469497A JP 2000502714 A JP2000502714 A JP 2000502714A
Authority
JP
Japan
Prior art keywords
hyaluronan
human body
body weight
oral administration
daltons
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP9524694A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000502714A5 (enExample
Inventor
アン ターリィ，イーヴァ
シモン アスキュライ，サミュエル
Original Assignee
ハイアル ファーマスティカル コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA002167044A external-priority patent/CA2167044C/en
Priority claimed from CA 2193921 external-priority patent/CA2193921A1/en
Application filed by ハイアル ファーマスティカル コーポレイション filed Critical ハイアル ファーマスティカル コーポレイション
Publication of JP2000502714A publication Critical patent/JP2000502714A/ja
Publication of JP2000502714A5 publication Critical patent/JP2000502714A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
JP9524694A 1996-01-11 1997-01-08 ヒアルロン酸の型の有効量の経口投与 Ceased JP2000502714A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CA002167044A CA2167044C (en) 1996-01-11 1996-01-11 Oral administration of effective amounts of forms of hyaluronic acid
CA2,193,921 1996-12-24
CA 2193921 CA2193921A1 (en) 1996-12-24 1996-12-24 Oral administration of effective amounts of forms of hyaluronic acid according to various standards
CA2,167,044 1996-12-24
PCT/CA1997/000007 WO1997025051A1 (en) 1996-01-11 1997-01-08 Oral administration of effective amounts of forms of hyaluronic acid

Publications (2)

Publication Number Publication Date
JP2000502714A true JP2000502714A (ja) 2000-03-07
JP2000502714A5 JP2000502714A5 (enExample) 2004-11-11

Family

ID=25678296

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9524694A Ceased JP2000502714A (ja) 1996-01-11 1997-01-08 ヒアルロン酸の型の有効量の経口投与

Country Status (11)

Country Link
US (1) US6537978B1 (enExample)
EP (1) EP0873128B1 (enExample)
JP (1) JP2000502714A (enExample)
AT (1) ATE282418T1 (enExample)
AU (1) AU732344B2 (enExample)
DE (1) DE69731610T2 (enExample)
ES (1) ES2231854T3 (enExample)
HU (1) HUP9902285A3 (enExample)
IL (2) IL124977A0 (enExample)
MX (1) MX9805588A (enExample)
WO (1) WO1997025051A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002161040A (ja) * 2000-11-27 2002-06-04 Taisho Pharmaceut Co Ltd 鉄イオン配合内服液剤
JP2005213210A (ja) * 2004-01-30 2005-08-11 Seikagaku Kogyo Co Ltd ヒアルロナン結合性タンパク質とヒアルロナンとの複合体の形成促進剤
JP2011042632A (ja) * 2009-08-24 2011-03-03 Q P Corp 経口用ドライアイ改善剤、ならびに前記経口用ドライアイ改善剤を含む食品組成物および医薬品組成物

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888984A (en) * 1994-05-12 1999-03-30 Dermal Research Laboratories, Inc. Pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
US6875753B1 (en) 1996-03-14 2005-04-05 The Governors Of The University Of Alberta Methods for cell mobilization using in vivo treatment with hyaluronan (HA)
CN1116044C (zh) * 1998-06-24 2003-07-30 凌沛学 含有透明质酸钠的防粘连颗粒剂和粉雾剂及其制作方法
EP1165097B1 (en) 1999-02-01 2007-05-02 Dermal Research Laboratories, Inc. A pharmaceutical composition of complex carbohydrates and their use
AU2005227417C1 (en) * 2000-07-31 2008-10-16 Dermal Research Laboratories, Inc. Methods of preventing or treating diseases and conditions using complex carbohydrates
US7879824B2 (en) 2001-07-31 2011-02-01 Dermal Research Laboratories, Inc. Methods of preventing or treating diseases and conditions using complex carbohydrates
JP4234439B2 (ja) * 2001-03-15 2009-03-04 生化学工業株式会社 Ｉｌ−１２発現調節剤
US7635489B2 (en) 2001-05-18 2009-12-22 Leneau Holdings, Llc Ingestion of hyaluronic acid for improved joint health
US6806259B2 (en) * 2001-12-21 2004-10-19 Soft Gel Technologies, Inc. Hyaluronic Acid in soft gel form
EP1476471A4 (en) * 2002-01-23 2005-03-16 Inst Of Nutraceutical Res Pty FUNCTIONAL FOODS FOR THE TREATMENT, PROTECTION AND RESTORATION OF CONNECTIVE TISSUES
DE10246340A1 (de) * 2002-10-04 2004-04-29 Wohlrab, David, Dr. Kombinationspräparat aus Hyaluronsäure und mindestens einem Lokalanästhetikum und dessen Verwendung
US7060691B2 (en) * 2002-10-10 2006-06-13 Giuseppe Petrigni Pharmaceutical colloidal preparation useful in the treatment of respiratory diseases
US7956180B2 (en) * 2004-05-27 2011-06-07 Novozymes A/S Dried and agglomerated hyaluronic acid product
US7405871B2 (en) * 2005-02-08 2008-07-29 Intel Corporation Efficient EUV collector designs
US8598144B1 (en) 2005-11-10 2013-12-03 Reyn Pharma, Llc Method of administering hyaluronan formulation for the amelioration of osteoarthritis
US9492381B1 (en) 2005-11-10 2016-11-15 Reyn Pharma, Llc Method of administering hyaluronan formulation for preventing and ameliorating osteoarthritis
US20080051367A1 (en) * 2006-08-23 2008-02-28 Huan-Ching Hsu Hyaluronan used in improvement of anti-oxidation and proliferation in chondrocytes
WO2008060466A2 (en) * 2006-11-10 2008-05-22 Cytori Therapeutics, Inc. Individualized dosage determination for local administration of therapeutic particles
US8163716B1 (en) 2008-06-30 2012-04-24 Smith James D Method of administering hyaluronan formulation for the amelioration of osteophytes
US8178511B1 (en) 2008-07-02 2012-05-15 Smith James D Method of administering hyaluronan formulation for the amelioration of osteopenia
US8462765B2 (en) * 2008-08-20 2013-06-11 Qualcomm Incorporated Method and apparatus to perform ranging operations for wireless stations
WO2012154738A1 (en) 2011-05-09 2012-11-15 The Cleveland Clinic Foundation Composition and method to improve intestinal health
WO2015022670A1 (en) * 2013-08-14 2015-02-19 Stempeutics Research Pvt. Ltd. Management of osteoarthritis using pooled allogeneic mesenchymal stem cells
DE202017107170U1 (de) 2017-11-27 2018-02-16 Proceanis Gmbh Hyaluronanhaltige orale Zusammensetzung
CN112972490B (zh) * 2021-03-04 2022-02-18 中国人民解放军军事科学院军事医学研究院 透明质酸在用于制备预防或治疗铁死亡相关疾病的药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0240098A3 (en) * 1986-04-04 1989-05-10 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Oligo and polysaccharides for the treatment of diseases caused by retroviruses
CA1340994C (en) 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
WO1994007505A1 (en) 1991-07-03 1994-04-14 Norpharmco Inc. Use of hyaluronic acid and forms to prevent arterial restenosis
US5834444A (en) * 1991-07-03 1998-11-10 Hyal Pharmaceutical Corporation Hyaluronic acid and salts thereof inhibit arterial restenosis
FR2691066B1 (fr) * 1992-05-15 1995-06-09 Sanofi Elf Utilisation de glycosaminoglycanes exogenes, de leurs analogues ainsi que de leurs fragments, fractions et derives, pour la preparation de medicaments destines au traitement de thrombopenies.

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002161040A (ja) * 2000-11-27 2002-06-04 Taisho Pharmaceut Co Ltd 鉄イオン配合内服液剤
JP2005213210A (ja) * 2004-01-30 2005-08-11 Seikagaku Kogyo Co Ltd ヒアルロナン結合性タンパク質とヒアルロナンとの複合体の形成促進剤
JP2011042632A (ja) * 2009-08-24 2011-03-03 Q P Corp 経口用ドライアイ改善剤、ならびに前記経口用ドライアイ改善剤を含む食品組成物および医薬品組成物

Also Published As

Publication number Publication date
AU732344B2 (en) 2001-04-12
HUP9902285A3 (en) 2001-07-30
EP0873128B1 (en) 2004-11-17
WO1997025051A1 (en) 1997-07-17
HUP9902285A2 (hu) 1999-11-29
MX9805588A (es) 1998-10-31
US6537978B1 (en) 2003-03-25
DE69731610D1 (de) 2004-12-23
ATE282418T1 (de) 2004-12-15
ES2231854T3 (es) 2005-05-16
EP0873128A1 (en) 1998-10-28
IL124977A0 (en) 1999-01-26
IL124977A (en) 2006-10-31
DE69731610T2 (de) 2005-12-01
AU1187697A (en) 1997-08-01

Similar Documents

Publication Publication Date Title
AU732344B2 (en) Oral administration of effective amounts of forms of hyaluronic acid
US6022866A (en) Use of hyaluronic acid and forms to prevent arterial restenosis
JP2567393B2 (ja) 哺乳動物へのヒアルロン酸の遠隔投与
US5614506A (en) Use of hyaluronic acid and forms to prevent arterial restenosis
US8367642B2 (en) Methods of preventing or treating diseases and conditions using complex carbohydrates
HU220758B1 (hu) Eljárás hialuronsavat és nem szteroid gyulladásgátlót tartalmazó, rák kezelésére alkalmas gyógyászati készítmények előállítására
CA2417867C (en) Methods of preventing or treating diseases and conditions using complex carbohydrates
JPH09512797A (ja) 癌の治療および転移の予防
AU2001281368A1 (en) Methods of preventing or treating diseases and conditions using complex carbohydrates
US5834444A (en) Hyaluronic acid and salts thereof inhibit arterial restenosis
HUT74462A (en) Compositions for inhibition of angiogenesis, containing hyaluronic acid and nonsteroidal anti-inflammatory agents
CA2175282A1 (en) Use of forms of hyaluronic acid (ha) for the treatment of cancer
AP619A (en) Use of hyaluronic acid or salt for the treatment of a human having a stroke or myocardial infarction.
WO1999002151A1 (en) Paclitaxel compositions containing hyaluronic acid of a molecular weight of less than 750.000 da
AP448A (en) Use of hyaluronic acid and forms to prevent arterial restenosis.
JP3811500B2 (ja) 動脈硬化の除去のためのヒアルロン酸を含む薬剤組成物
JP2000513707A (ja) 投与薬剤の目標化、治療薬および他のグリコサミノグリカン（ｇａｇｓ）
CA2167044C (en) Oral administration of effective amounts of forms of hyaluronic acid
CA2193921A1 (en) Oral administration of effective amounts of forms of hyaluronic acid according to various standards
US20140194378A1 (en) Methods of Preventing or Treating Diseases and Conditions Using Complex Carbohydrates
AU2005227417C1 (en) Methods of preventing or treating diseases and conditions using complex carbohydrates
AU702929B2 (en) Use of hyaluronic acid and forms to prevent arterial restenosis
NZ299942A (en) Use of hyaluronic acid (or fragments thereof) to prevent narrowing of tubular walls in an animal (typically arterial restenosis)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040105

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080304

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080527

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20081014

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20081209